14
Views
2
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

Antiretroviral therapy during infancy: essential intervention for resource-limited settings

Pages 585-589 | Published online: 10 Jan 2014

References

  • Prendergast A, Mphatswe W, Tudor-Williams G et al. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants. AIDS22, 1333–1343 (2008).
  • HIV Paediatric Prognostic Markers Collaborative Study Group. Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet362, 1605–1611 (2003).
  • Janssens B, Raleigh B, Soeung S et al. Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia. Pediatrics120, E1134–E1140 (2007).
  • George E, Noël F, Bois G et al. Antiretroviral therapy for HIV-1-infected children in Haiti. J. Infect. Dis.195, 1411–1418 (2007).
  • Wamalwa DC, Farquhar C, Obimbo EM et al. Early response to highly active antiretroviral therapy in HIV-1-infected Kenyan children. J. Acquir. Immune Defic. Syndr.45, 311–317 (2007).
  • Reddi A, Leeper SC, Grobler AC et al. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa. BMC Pediatr.7, 13 (2007).
  • Kamya MR, Mayanja-Kizza H, Kambugu A et al. Predictors of long-term viral failure among Ugandan children and adults treated with antiretroviral therapy. J. Acquir. Immune Defic. Syndr.46, 187–193 (2007).
  • Eley B, Davies M, Apolles P et al. Antiretroviral treatment for children. S. Afr. Med. J.96, 988–993 (2006).
  • Rouet F, Fassinou P, Inwoley A et al. Long-term survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens. AIDS20, 2315–2319 (2006).
  • Puthanakit T, Oberdorfer A, Akarathum N et al. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand’s national access to antiretroviral program. Clin. Infect. Dis.41, 100–107 (2005).
  • Newell M, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F; for the Ghent International AIDS Society (AIS) working group on HIV infection in women and children. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet364, 1236–1243 (2007).
  • Mills EJ, Nachega JB, Buchan I et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. J. Am. Med. Assoc.296, 679–690 (2006).
  • Faye A, Le Chenadec J, Dollfus C et al. Early versus deferred antiretroviral multidrug therapy in infants infected with HIV type 1. Clin. Infect. Dis.39, 1692–1698 (2004).
  • Violari A, Cotton M, Gibb D et al. Antiretroviral therapy initiated before 12 weeks of age reduces early mortality in young HIV-infected infants: evidence from the Children with HIV Early Antiretroviral Therapy (CHER) Study. Presented at: 4th IAS Conference Sydney, Australia, 22–25 July 2007.
  • Luzuriaga K, McManus M, Mofenson L et al. A trial of three antiretroviral regimens in HIV-1 infected children. N. Engl. J. Med.350, 2471–2480 (2004).
  • Cherutich P, Inwani I, Nduati R, Mbori-Ngacha D. Optimizing paediatric HIV care in Kenya: challenges in early infant diagnosis. Bull. World Health Organ.86, 155–160 (2008).
  • INITIO Trial International Co-ordinating Committee. Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomized trial. Lancet368, 287–298 (2006).
  • Gulick RM, Ribaudo HJ, Shikuma CM et al. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. J. Am. Med. Assoc.296, 769–781 (2006).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.